Cargando…
Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients
BACKGROUND AND AIM: Crohn's disease (CD) is a chronic inflammatory condition of the gastrointestinal tract with the potential to progress to a severe debilitating state. Treatment with biological agents is highly efficient, improving both short-term outcomes and long-term prognosis. Nonetheless...
Autores principales: | Pagnini, Cristiano, Siakavellas, Spyros I., Bamias, Giorgos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079437/ https://www.ncbi.nlm.nih.gov/pubmed/30116266 http://dx.doi.org/10.1155/2018/6317057 |
Ejemplares similares
-
The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era
por: Evangelatos, Gerasimos, et al.
Publicado: (2022) -
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022) -
Intestinal-Specific TNFα Overexpression Induces Crohn’s-Like Ileitis in Mice
por: Bamias, Giorgos, et al.
Publicado: (2013) -
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023) -
Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)